Results 21 to 30 of about 198,266 (267)

Delayed esophageal anastomotic complication and ramucirumab therapy: A case report

Thoracic Cancer, 2023
Current NCCN guidelines for second‐line therapy in recurrent or metastatic esophago‐gastric cancers recommend the use of VEGF inhibitors such as ramucirumab.
Robert H. Roth, Madison J. Malfitano, Matthew Reilley, Linda W. Martin   +3 more
doaj   +1 more source

Hiccups as the First Symptom of a Complication of Total Gastrectomy for Gastric Cancer with a Negative Objective Abdominal Examination: A Case Report and Review of the Literature

Gastroenterology Insights
Total gastrectomy with D2 lymphadenectomy for gastric cancer is a complex surgical procedure with a moderate complication rate. Sometimes, some complications may have a misleading onset without a clear clinical presentation and blood test changes.
Francesco Lamacchia, Genny Mattara, Francesca Tolin, Beatrice Maddalon, Pierluigi Pilati   +4 more
doaj   +1 more source

Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma

BMC Cancer, 2018
Background Esophageal sarcomatoid carcinoma (ESC) is a rare disease with a mixture of both carcinomatous and sarcomatous components in the tumor. Its genetic background and mechanisms of oncogenesis remain largely unknown.
Hongyang Lu, Shifeng Yang, Huineng Zhu, Xiaoling Tong, Fajun Xie, Jing Qin, Na Han, Xue Wu, Yun Fan, Yang W. Shao, Weimin Mao   +10 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Surgical technique of da Vinci robotic-assisted minimally invasive esophagectomy(RAMIE) expert experiences

Intelligent Surgery
Esophageal cancer is a prevalent disease in thoracic surgery, and surgery is currently the main treatment method. It can completely remove the tumor and improve the patient's quality of life.
Chengyuan Fang, Luquan Zhang, Hao Liang, Yanzhong Xin, Wei Zheng, Jianqun Ma   +5 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Risk factors and prediction models for severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing chemoradiotherapy

Discover Oncology
Objective This study aimed to investigate the factors associated with severe radiation-induced oral mucositis (SRIOM) in nasopharyngeal carcinoma (NPC) patients undergoing chemoradiotherapy (CRT) and to establish a prediction model for SRIOM.
Yi Liang, XiaoQin Wang, XunRen Shi, XinXiong Fei   +3 more
doaj   +1 more source

Is It Barrett's Esophagus or Gastric Heterotopia

Case Reports in Gastroenterology, 2014
Columnar epithelium in the distal part of the esophagus is generally related to Barrett's esophagus. Barrett's esophagus is a well-known premalignant lesion for adenocarcinoma of the esophagus.
Zeynel Mungan
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source